Abstract
While allogeneic hematopoietic stem cell transplantations have a curative potential, several patients with hematologic malignancies cannot avail themselves of this therapeutic option due to lack of matched donor availability. Although HLA-haploidentical transplantations were previously associated with poor outcomes, recent evidence with use of post transplantation cyclophosphamide indicate improved safety and efficacy. The following paper discusses the most recent developments in this area.
Original language | English (US) |
---|---|
Pages (from-to) | 141-146 |
Number of pages | 6 |
Journal | Best Practice and Research: Clinical Haematology |
Volume | 28 |
Issue number | 2-3 |
DOIs | |
State | Published - Jun 1 2015 |
Keywords
- Acute myeloid leukemia
- Cyclophosphamide
- Graft versus host disease
- HLA-haploidentical transplantation
- Matched related donor
- Matched unrelated donor
- Mismatched unrelated donor
- Relapse
ASJC Scopus subject areas
- Oncology
- Clinical Biochemistry